The SMART ART Study

Sponsor
University of Washington (Other)
Overall Status
Recruiting
CT.gov ID
NCT05090150
Collaborator
National Institute of Mental Health (NIMH) (NIH)
900
1
6
58
15.5

Study Details

Study Description

Brief Summary

The investigators propose A Sequential Multiple Assignment Randomized Trial of scalable interventions for ART delivery in South Africa- the SMART ART study-a randomized study to test adaptive ART delivery for persons with detectable viral load and/or not engaged in care.The types of differentiated service delivery (DSD) that will be examined in this study are incentives, community-based ART, and home delivery. The study plans to enroll up to 900 participants-people living with HIV and who are eligible for ART and living in KwaZulu-Natal, South Africa. The study aims to maximize the proportion of ART eligible persons living with HIV who achieve viral suppression at 18 months. The study will also evaluate the preferences of clients and providers for differentiated service delivery, and evaluate the cost effectiveness of adaptive HIV treatment for those who are not engaged in care.

Condition or Disease Intervention/Treatment Phase
  • Other: Home delivery of ART
  • Other: Smart Lockers (Pele boxes)
  • Other: Best clinic practices + conditional lottery incentives
  • Other: Best clinic practices
N/A

Detailed Description

Of the 8 million people in South Africa living with HIV, only 56% are on antiretroviral therapy (ART), and 45% are virally suppressed, substantially below the UNAIDS goal of 73%. Detectable viral load results in HIV-associated morbidity and mortality, and HIV transmission. Patient barriers to care, such as missed wages, transport costs, and long wait times for clinic visits and ART refills, are associated with detectable viral load. HIV differentiated service delivery (DSD) has simplified ART delivery: incentives, multi-month scripts, fast-track ART, and community or home ART delivery motivate clients, reduce the frequency of clinic visits, and decongest clinics. DSD is standard for clients who achieve viral suppression and engage in care; however, DSD needs adaptation to serve clients who are not succeeding. Indeed, persons who are not engaged in care arguably need simplified, client-centered approaches even more than those who can successfully engage.

A suite of adaptive DSD strategies, including incentives strategies, community-based ART, and home delivery, have been tested among stable clients with viral suppression. Lottery incentives effectively change short-term behavior, increasing ART initiation.Community-based and home ART delivery increase ART coverage and simplify ART access overcoming clinic barriers11. For stable clients, these DSD activities are as effective as clinic-based care in terms of achieving and maintaining viral suppression, although among stable clients they have not shown superiority in viral suppression or cost savings. In contrast, DSD has the potential to improve rates of viral suppression and retention in care and save costs among persons not engaged in care. There is great potential that DSD systems can be client-responsive and system-efficient for subgroups requiring additional services, matching services with client needs. A sequential, comprehensive package of DSD approaches, with each step increasing the intensity of service provision - adaptive DSD - has not been tested to determine the proportion and characteristics of persons who would achieve viral suppression and retention in care and to estimate the cost-effectiveness and budget impact.

To increase population level viral suppression, persons with detectable viral load need responsive DSD interventions. A Sequential Multiple Assignment Randomized Trial (SMART) design facilitates evaluation of a stepped, adaptive approach to achieving viral suppression with 'right-sized' interventions. The investigators are an experienced team and propose to build on the strong partnerships to sequentially test adaptive DSD strategies for persons with detectable viral load and/or not engaged in care: incentives, community-based ART, and home delivery. As the Center for Community Based Research, the investigators maintain strong connections with stakeholders including department of health, traditional leaders and ward counsellors throughout the Greater Edendale Area (GEA) and the Vulindlela sub-district of the uMgungundlovu District Municipality. Due to the size of the recruitment target, this work will centre around the Caluza clinic but will extend into other parts of GEA and sub-district of Vulindlela over the course of recruitment. The aim is to identify the most effective and efficient HIV care delivery strategies.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
900 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
Participants are first randomly assigned to two interventions:either best clinic practices or best clinic practices with a conditional lottery incentive. This stage lasts 6 months. Participants who do not meet the criteria for non-response will continue in the assigned intervention arm. Non-responders will be rerandomized to continue in the clinic intervention arm (standard of care), community ART (smart lockers), or home delivery.Participants are first randomly assigned to two interventions:either best clinic practices or best clinic practices with a conditional lottery incentive. This stage lasts 6 months. Participants who do not meet the criteria for non-response will continue in the assigned intervention arm. Non-responders will be rerandomized to continue in the clinic intervention arm (standard of care), community ART (smart lockers), or home delivery.
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
A Sequential Multiple Assignment Randomized Trial of Scalable Interventions for ART Delivery in South Africa: the SMART ART Study
Actual Study Start Date :
Nov 2, 2021
Anticipated Primary Completion Date :
Sep 1, 2026
Anticipated Study Completion Date :
Sep 1, 2026

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Best clinic practices

Participants start with best clinic practices and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in their original arm)

Experimental: Best clinic practices plus lottery incentives

Participants start with best clinic practices plus lottery incentives and continue for 18 months (including participants who are non-responders at month 6 and are randomized to stay in the original arm)

Other: Best clinic practices + conditional lottery incentives
Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Experimental: Randomized from best clinic practices to smart lockers

Second randomization into community ART through the use of smart lockers

Other: Smart Lockers (Pele boxes)
Decentralized ART refills and monitoring, adherence support

Other: Best clinic practices
Continue with best clinic practices

Experimental: Randomized from best clinic practices to home delivery

Second randomization into home ART delivery

Other: Home delivery of ART
Home ART refill and monitoring, adherence support

Other: Best clinic practices
Continue with best clinic practices

Experimental: Randomized from best clinic practices plus lottery incentives to smart lockers

Second randomization into community ART through the use of smart lockers

Other: Smart Lockers (Pele boxes)
Decentralized ART refills and monitoring, adherence support

Other: Best clinic practices + conditional lottery incentives
Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Experimental: Randomized from best clinic practices plus lottery incentives to home delivery

Second randomization into home ART delivery

Other: Home delivery of ART
Home ART refill and monitoring, adherence support

Other: Best clinic practices + conditional lottery incentives
Conditional lottery incentives Welcome back service (friendly providers, SMS, adherence support) Fast-track ART

Outcome Measures

Primary Outcome Measures

  1. Viral suppression at 18 months [18 months]

    The primary outcome is viral suppression at 18 months among the combined group of persons living with HIV who have detectable viral load and persons not engaged in care at enrollment.

Secondary Outcome Measures

  1. Retention in Care [12 months]

    The proportion of clinical visits and medication refills missed over the last 12 months of the intervention

  2. Time to ART initiation [6 months]

    Time to antiretroviral therapy initiation

  3. Engagement in care [18 months]

    Proportion of people who are virally suppressed in each intervention arm

  4. Comparison to viral suppression and retention outcomes from similar local clinics [18 months]

    Proportion of individuals who are virally suppressed who are engaged in care in intervention arms compared to local clinics

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Must be 18 years or older

  • Able and willing to provide informed consent for study procedures

  • Must self report that they will reside in the study community for the duration of follow-up

  • Living with HIV and eligible for ART by national guidelines, have a detectable viral load greater than the lower limit of detection and/or not engaged in care, and are stable clinically (CD4>100 cells, no moderate/severe screening laboratory abnormalities for kidney function i.e. eGFR >50 mL/min/1.73m2, not receiving treatment for active tuberculosis or other opportunistic infections).

Exclusion Criteria:
  • There are no separate exclusion criteria.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Human Sciences Research Council Sweetwaters Sweetwaters Kwa-zulu Natal South Africa

Sponsors and Collaborators

  • University of Washington
  • National Institute of Mental Health (NIMH)

Investigators

  • Principal Investigator: Ruanne V Barnabas, DPhil, University of Washington

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ruanne Barnabas, Associate Professor: Global Health, University of Washington
ClinicalTrials.gov Identifier:
NCT05090150
Other Study ID Numbers:
  • STUDY00013492
  • R01MH124465
First Posted:
Oct 22, 2021
Last Update Posted:
Nov 16, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Nov 16, 2021